A phase I trial examining the benefit of treatment with BPI-7711, that included 85 patients with advanced or recurrent EGFRm+/T790M+ NSCLC who had progressed after 1st/2nd generation of EGFR TKIs were enrolled into 5 dose escalation cohorts (30/60/120/180/240 mg). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.